What is the clinical evidence from this study?

Study design: Observational. Population: Calcific Aortic Valve Stenosis (n=1066048). Intervention: C4B expression vs. Lower or reference C4B expression. Primary outcome: Calcific aortic valve stenosis (OR 1.04, 95% CI 1.03-1.06, p=3.49 × 10-9).

What question did this study set out to answer?

This research aims to identify potential drug targets for calcific aortic valve stenosis through multi-omic analyses and Mendelian randomization.

July 9, 2026Cardiovascular Drugs and TherapyOpen Access

Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis

Q: What are the key findings of this study?

Genetically predicted higher C4B expression was identified as a risk factor for calcific aortic valve stenosis (OR 1.04), and C4B protein was significantly upregulated in human calcific aortic valves.

View Full Paper

Ask AI

Bookmark

Key result

Higher genetically predicted C4B expression is linked to ~4% greater calcific aortic valve stenosis risk.

OR 1.04
95% CI 1.03-1.06
P=3.49 × 10-9
n=1,066,048

Key Points

This research aims to identify potential drug targets for calcific aortic valve stenosis through multi-omic analyses and Mendelian randomization.
Integrated druggable genome with cis-eQTL data from eQTLGen Consortium.
Conducted Mendelian randomization using two independent GWAS datasets for CAVS.
Validated findings through proteomic analysis and immunohistochemical assessment of human aortic valves.
C4B was established as a risk factor for CAVS with an odds ratio of 1.04 (95% CI: 1.03–1.06, p = 3.49 × 10−9).
LC-MS/MS confirmed significant upregulation of C4B (fold change 1.51, p < 0.05).
IHC analysis showed higher expression of C4B in calcific valves (1916.95 ± 1118.89 vs. 502.34 ± 474.27; p = 0.025).

Study Design

Type

Observational (n=1,066,048)

Multicenter

Yes

Structured PICO

Population

1,066,048 individuals of predominantly European ancestry from the FinnGen and other European cohorts analyzed via Mendelian randomization to identify genetic proxies for drug targets associated with calcific aortic valve stenosis.

Exposure

Genetic proxies for druggable targets (specifically complement component C4B)

Outcome

Association with calcific aortic valve stenosis (CAVS)surrogate

Main Result

Odds Ratio: 1.04 (95% CI 1.03–1.06)

p-value: p=3.49 × 10-9

Multi-omic and Mendelian randomization analyses identify complement component C4B as a novel genetically anchored therapeutic target for calcific aortic valve stenosis.

Limitations

GWAS and eQTL data are predominantly derived from individuals of European ancestry, limiting generalizability to other ethnic groups.
Proteomic and immunohistochemical validations were performed with modest sample sizes.
Exclusive use of blood-derived eQTLs may not fully capture tissue-specific regulation in the aortic valve.
Stringent Bonferroni correction for multiple testing may elevate the risk of Type II errors (false negatives).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Identifies actionable CAVS drug targets; extends multi-omic MR evidence to prioritize candidates for development.

Cite This Study

Li et al. (2026) conducted an observational in Calcific Aortic Valve Stenosis (n=1,066,048). C4B expression vs. Lower or reference C4B expression was evaluated on Calcific aortic valve stenosis (OR 1.04, 95% CI 1.03-1.06, p=3.49 × 10-9). Genetically predicted higher C4B expression was identified as a risk factor for calcific aortic valve stenosis (OR 1.04), and C4B protein was significantly upregulated in human calcific aortic valves.

synapsesocial.com/papers/6a4f3bb72b81a944af5757d2 https://doi.org/10.1007/s10557-026-07896-1

View Full Paper

Ask AI

Bookmark

Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider